What is Create Medicines?
Create Medicines operates as a clinical-stage biotechnology enterprise dedicated to the development of in vivo immune programming therapies. The company utilizes a proprietary mRNA-LNP platform to engineer T cells, NK cells, and myeloid cells directly inside the human body. This innovative approach facilitates the creation of scalable, repeat-dose, and off-the-shelf immunotherapies that aim to redefine treatment paradigms for oncology and autoimmune diseases. By utilizing RNA-based CAR approaches, the firm seeks to improve patient accessibility, reduce the inherent complexity of current cell-based treatments, and enable highly programmable immune responses. This technological differentiation positions Create Medicines as a critical player in the next generation of precision medicine.
How much funding has Create Medicines raised?
Create Medicines has raised a total of $134M across 2 funding rounds:
Seed
$12M
Series B
$122M
Seed (2019): $12M, investors not publicly disclosed
Series B (2026): $122M led by Alexandria, Hatteras Venture Partners, ARCH Venture Partners, and Newpath Partners
Key Investors in Create Medicines
Alexandria
Alexandria Real Estate Equities is a specialized REIT that provides essential laboratory and office infrastructure for the life sciences industry, supporting the growth of innovative biotech firms.
Hatteras Venture Partners
Hatteras Venture Partners is a venture capital firm focused on building transformative companies in the biotech, MedTech, and HealthTech sectors, providing both capital and strategic operational support.
ARCH Venture Partners
ARCH Venture Partners is a leading early-stage venture capital firm that specializes in co-founding and investing in life sciences and advanced technology companies to commercialize breakthrough innovations.
What's next for Create Medicines?
With the successful closure of this major enterprise-level funding, Create Medicines is well-positioned to advance its clinical programs and expand its research capabilities. The strategic focus will likely shift toward scaling its manufacturing processes and accelerating the transition of its lead candidates through human clinical trials. By leveraging the expertise of its high-profile investor syndicate, the company is expected to refine its operational efficiency and strengthen its intellectual property portfolio. As the firm continues to navigate the complexities of the biotech sector, the focus remains on delivering transformative therapeutic outcomes that address significant unmet medical needs in oncology and immunology, ultimately aiming to establish a new standard for off-the-shelf, programmable immune therapies.
See full Create Medicines company page
